ClearPoint Neuro (CLPT) Expected to Announce Quarterly Earnings on Thursday

ClearPoint Neuro (NASDAQ:CLPT) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.60 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $9.22 million during the quarter, compared to analysts’ expectations of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

Shares of ClearPoint Neuro stock opened at $17.52 on Wednesday. The business’s fifty day simple moving average is $18.93 and its 200 day simple moving average is $14.46. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. ClearPoint Neuro has a 12 month low of $9.76 and a 12 month high of $30.10. The firm has a market capitalization of $498.04 million, a P/E ratio of -21.63 and a beta of 1.19.

Insider Activity

In related news, CEO Joseph Burnett sold 26,463 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $26.98, for a total transaction of $713,971.74. Following the sale, the chief executive officer directly owned 217,059 shares in the company, valued at approximately $5,856,251.82. This represents a 10.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ClearPoint Neuro

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after acquiring an additional 2,143 shares during the period. Legal & General Group Plc purchased a new stake in ClearPoint Neuro during the 2nd quarter worth about $35,000. Raymond James Financial Inc. bought a new position in ClearPoint Neuro in the 2nd quarter worth about $80,000. Osaic Holdings Inc. grew its holdings in ClearPoint Neuro by 119.8% during the 2nd quarter. Osaic Holdings Inc. now owns 7,705 shares of the company’s stock valued at $92,000 after buying an additional 4,200 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of ClearPoint Neuro during the second quarter valued at about $100,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

Analyst Ratings Changes

CLPT has been the topic of several research reports. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded ClearPoint Neuro from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.